Pentacel vaccine consists of Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus (DTaP-IPV) component and an ActHIB® vaccine component
Pentacel Vaccine Discounts
Pentacel vaccine discounts can be found here sponsored by GoodRx
Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to H influenzae type b.
Pentacel is administered as an intramuscular injection.
Pentacel vaccine is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to the fifth birthday).
June 23, 2008 - Sanofi Pasteur, announced that the U.S. Food and Drug Administration (FDA) has licensed Pentacel® vaccine that is approved for use in infants and children 6 weeks through 4 years of age (prior to the fifth birthday).
Pentacel® vaccine is the first and only four-dose diphtheria, tetanus, and acellular pertussis (DTaP)-based combination vaccine for use in infants and young children in the U.S. that includes both poliovirus and Hib antigens.